Natixis Advisors LLC Acquires 6,790 Shares of Solventum Co. (NYSE:SOLV)

Natixis Advisors LLC increased its stake in Solventum Co. (NYSE:SOLV - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 54,406 shares of the company's stock after purchasing an additional 6,790 shares during the quarter. Natixis Advisors LLC's holdings in Solventum were worth $3,594,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the stock. Diamond Hill Capital Management Inc. bought a new position in Solventum in the 4th quarter worth about $15,913,000. Madison Investment Advisors LLC purchased a new stake in shares of Solventum in the fourth quarter worth about $322,000. Thompson Siegel & Walmsley LLC boosted its position in shares of Solventum by 1.1% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 111,937 shares of the company's stock valued at $7,395,000 after acquiring an additional 1,218 shares during the period. Skandinaviska Enskilda Banken AB publ grew its stake in Solventum by 51.6% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 82,767 shares of the company's stock valued at $5,467,000 after acquiring an additional 28,154 shares in the last quarter. Finally, Achmea Investment Management B.V. increased its holdings in Solventum by 4.5% during the 4th quarter. Achmea Investment Management B.V. now owns 16,332 shares of the company's stock worth $1,079,000 after acquiring an additional 710 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have commented on SOLV. Bank of America raised their price target on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Wednesday, February 26th. Wells Fargo & Company lifted their price objective on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research note on Friday, February 28th. Piper Sandler upped their target price on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Morgan Stanley raised their price target on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. Finally, Mizuho raised their target price on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $79.86.

Remove Ads

Solventum Trading Down 0.9 %

SOLV stock traded down $0.68 during midday trading on Wednesday, hitting $74.25. The company had a trading volume of 1,900,369 shares, compared to its average volume of 1,428,247. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The stock has a market cap of $12.84 billion and a price-to-earnings ratio of 27.00. The stock's 50 day moving average price is $75.38 and its 200 day moving average price is $71.73.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.